Secukinumab, a novel anti-interleukin-17A antibody, exhibits low immunogenicity during long-term treatment in subjects with psoriasis

被引：0
|
作者：
Reich, K. [1 ,2 ]
Blauvelt, A. [3 ]
Armstrong, A. [4 ]
Fox, T. [5 ]
Huang, J. [5 ]
Lloyd, P. [5 ]
Bruin, G. [5 ]
机构：
[1] Dermatologikum Hamburg, Hamburg, Germany
[2] Univ Gottingen, Hamburg, Germany
[3] Oregon Med Res Ctr, Portland, OR USA
[4] Univ Colorado, Denver Sch Med, Aurora, CO USA
[5] Novartis Pharma AG, Basel, Switzerland
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2014年 / 171卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P103
引用
收藏
页码：E166 / E167
页数：2
相关论文
共 50 条
  • [1] Secukinumab, a novel anti-IL-17A antibody, exhibits low immunogenicity during long-term treatment in subjects with moderate to severe plaque psoriasis
    Reich, Kristian
    Blauvelt, Andrew
    Armstrong, April
    Fox, Todd
    Huang, Jiaqing
    Bruin, Gerard
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S15 - S15
  • [2] Secukinumab, a novel anti-interleukin-17A antibody, exhibits low immunogenicity potential according to human in vitro assays
    Karle, A.
    Spindeldreher, S.
    Kolbinger, F.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 (06) : E164 - E164
  • [3] Ixekizumab, a novel anti-IL-17A antibody, exhibits low immunogenicity during long-term treatment in patients with psoriasis
    Blauvelt, A.
    Langley, R.
    Leonardi, C.
    Gordon, K.
    Luger, T.
    Ohtsuki, M.
    Nickoloff, B.
    Kerr, L.
    Mallbris, L.
    Reich, K.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (09) : S227 - S227
  • [4] Ixekizumab, a novel anti-IL-17A antibody, exhibits low immunogenicity during long-term treatment in patients with psoriasis
    Blauvelt, Andrew
    Langley, Richard
    Leonardi, Craig
    Gordon, Kenneth
    Luger, Thomas
    Ohtsuki, Mamitoro
    Nickoloff, Brian
    Kerr, Lisa
    Cameron, Gregory
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB258 - AB258
  • [5] Ixekizumab, a novel anti-IL-17A antibody, exhibits low immunogenicity during long-term treatment in patients with psoriasis
    Blauvelt, A.
    Langley, R. G.
    Leonardi, C.
    Gordon, K.
    Luger, T.
    Ohtsuki, M.
    Nickoloff, B. J.
    Kerr, L. F.
    Cameron, G. S.
    Mallbris, L.
    Muram, T.
    Konrad, R.
    Komocsar, W.
    Leutz, A.
    Reich, K.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 107 - 108
  • [6] Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years
    Reich, K.
    Blauvelt, A.
    Armstrong, A.
    Langley, R. G.
    de Vera, A.
    Kolbinger, F.
    Spindeldreher, S.
    Ren, M.
    Bruin, G.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (09) : 1733 - 1741
  • [7] Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis
    Reich, K.
    Blauvelt, A.
    Armstrong, A.
    Langley, R. G.
    Fox, T.
    Huang, J.
    Papavassilis, C.
    Liang, E.
    Lloyd, P.
    Bruin, G.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 176 (03) : 752 - 758
  • [8] SECUKINUMAB, A FULLY HUMAN ANTI-INTERLEUKIN-17A MONOCLONAL ANTIBODY, EXHIBITS LOW IMMUNOGENICITY IN PATIENTS WITH PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS DURING A 52-WEEK TREATMENT PERIOD
    Deodhar, A.
    Gladman, D.
    Mclnnes, I.
    Ren, M.
    Spindeldreher, S.
    Pricop, L.
    Porter, B.
    Safi, J.
    Shete, A.
    Bruin, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 999 - 1000
  • [9] SECUKINUMAB, A FULLY HUMAN ANTI-INTERLEUKIN-17A MONOCLONAL ANTIBODY, EXHIBITS LOW IMMUNOGENICITY IN PATIENTS WITH PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS DURING A 52WEEK TREATMENT PERIOD
    McInnes, Iain B.
    Deodhar, Atul
    Gladman, Dafna D.
    Ren, Mengyuan
    Spindeldreher, Sebastian
    Pricop, Luminita
    Porter, Brian
    Safi, Jorge
    Shete, Abhijit
    Bruin, Gerard
    RHEUMATOLOGY, 2019, 58
  • [10] Secukinumab exhibits low immunogenicity during 104 weeks of treatment in subjects with moderate to severe plaque psoriasis
    Sinclair, R.
    Reich, K.
    Blauvelt, A.
    Warren, R.
    Szepietowski, J.
    Sigurgeirsson, B.
    Langley, R.
    Tyring, S.
    Messina, I.
    Fox, T.
    Papavassilis, C.
    Bruin, G.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2016, 57 : 74 - 74
12345